Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT02840344 Completed - Breast Cancer Clinical Trials

Couples-Based Mindfulness for Young Breast Cancer Survivors

C-MBSR
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

This study aims to improve relationship, psychological, and physical adjustment among young breast cancer survivors (YBCS; diagnosed at age 45 or younger) and their committed/life partners. A mindfulness-based stress reduction (MBSR) intervention has been designed to meet the specific needs for young breast cancer survivors and their partners. The intervention will be administered in your home by using recorded videos of a trained MBSR instructor. Before, during, and after the 8-week intervention, participants will be asked to complete surveys.

NCT ID: NCT02839668 Completed - Breast Cancer Clinical Trials

The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)

TIVA/TCI-BC
Start date: August 2016
Phase: Phase 2
Study type: Interventional

Because neoplastic disease is one of the leading causes of death worldwide and breast cancer is one of the most frequent neoplasia among women, the possibility of influencing the evolution of patients starting from the moment of surgical intervention using a perianesthesic intervention is a scientific topic of high interest. The study will compare two anesthetic techniques and their efficiency in lowering the factors that can favorize the dissemination of neoplasia and their role in the prevention of postoperative pain. The serum level of vascular endothelial growth factor A (VEGF-A) will be determined before and after the surgical intervention after using two different types of anesthesia (inhalational and intravenous), and the immunohistochemical expression of vascular endothelial growth factor receptors (VEGFR) will be determined on the excised tissue. For the two different types of anesthesia a continuous infusion of lidocaine 1% will be associated. The study will compare the short-term and long term-outcome of the patients assigned the two different types of anesthesia and their immediate postoperative evolution .

NCT ID: NCT02839473 Completed - Breast Cancer Clinical Trials

Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial

HYDROSORB
Start date: March 2010
Phase: Phase 3
Study type: Interventional

The primary objective consisted of avoiding deterioration and/or restoring the integrity of the skin of patients treated by radiotherapy, right from the first signs of grade 1 or 2 radiation dermatitis.

NCT ID: NCT02838823 Completed - Breast Cancer Clinical Trials

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with triple negative breast cancer who have failed in routine systemic treatment. The study will be conducted in 2 parts: dose escalation and cohort expansion to investigate tolerability and efficacy.

NCT ID: NCT02838225 Completed - Breast Cancer Clinical Trials

DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer

Start date: January 2009
Phase: Phase 2
Study type: Interventional

Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.

NCT ID: NCT02836093 Completed - Breast Cancer Clinical Trials

Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment

Start date: July 13, 2016
Phase:
Study type: Observational

Many patients receiving radiation therapy for breast cancer experience fatigue although doctors do not fully understand why. The purpose of this study is to test if patients who experience fatigue during radiation treatment for breast cancer have changes in their capability to perform exercise on a treadmill.

NCT ID: NCT02835781 Completed - Breast Cancer Clinical Trials

Acellular Dermal Matrix in Breast Reconstruction

Adermbrerec
Start date: January 2010
Phase: N/A
Study type: Observational

Allogenic acellular dermal matrix has been used in burn injuries or abdominal walls reconstructions. However, it is solely used in breast reconstructions after breast carcinoma amputation. The efficacy of such allogenic dermal matrix can be advantageous when compared to current treatment options, however, this has to be proved.

NCT ID: NCT02833233 Completed - Breast Cancer Clinical Trials

A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer

Start date: June 2016
Phase: N/A
Study type: Interventional

This study is being done to evaluate the safety of combining two strategies called "cryoablation" and "immune therapy" in women with curable early stage breast cancer.

NCT ID: NCT02833155 Completed - Breast Cancer Clinical Trials

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

Start date: August 29, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerance of entinostat administered orally as a single agent in a weekly dosing schedule. Additionally, this study will characterize the pharmacokinetics parameters in Chinese postmenopausal women with advanced breast cancer. And to define the profile of adverse events, including laboratory parameters in these subjects

NCT ID: NCT02831634 Completed - Breast Cancer Clinical Trials

A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)

Start date: June 9, 2016
Phase: N/A
Study type: Interventional

Feasibility study for a method allowing identification of tumor mutated epitopes in patients with breast cancer or cutaneous melanoma, and quantification of CD8+ T cells specific for these tumor neo-antigens in their lymph nodes